Xiubao Ren

Anti-CD47 Antibody As a Targeted Therapeutic Agent for Human Lung Cancer and Cancer Stem Cells.

Quality of Life after Autologous Peripheral Blood Stem Cell Transplantation and High-Dose Chemotherapy in High-Risk Breast Cancer Patients.

Increased prevalence of regulatory T cells in the lung cancer microenvironment: a role of thymic stromal lymphopoietin.

Upregulated expression of indoleamine 2, 3-dioxygenase in CHO cells induces apoptosis of competent T cells and increases proportion of Treg cells.

Therapeutic effect of intratumoral administration of DCs with conditional expression of combination of different cytokines.

Enhanced activation of human dendritic cells by silencing SOCS1 and activating TLRs simultaneously.

Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study.

Autophagy induced by conventional chemotherapy mediates tumor cell sensitivity to immunotherapy.

Over-expression of semaphorin4D, hypoxia-inducible factor-1α and vascular endothelial growth factor is related to poor prognosis in ovarian epithelial cancer.

Combining the negative lymph nodes count with the ratio of positive and removed lymph nodes can better predict the postoperative survival in cervical cancer patients.

Dysfunctional activation of neurotensin/IL-8 pathway in hepatocellular carcinoma is associated with increased inflammatory response in microenvironment, more epithelial mesenchymal transition in cancer and worse prognosis in patients.

Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer.

Current adoptive immunotherapy in non-small cell lung cancer and potential influence of therapy outcome.

Clinical implication of microrna for lung cancer.

A phase II, randomized, double-blind, placebo-controlled multicenter trial of Endostar in patients with metastatic melanoma.

The correlation between the subsets of tumor infiltrating memory T cells and the expression of indoleamine 2,3-dioxygenase in gastric cancer.

Diagnostic and prognostic value of circulating miR-21 for cancer: a systematic review and meta-analysis.

The role of phosphoglycerate mutase 1 in tumor aerobic glycolysis and its potential therapeutic implications.

Can the dual-functional capability of CIK cells be used to improve antitumor effects?

Primary hepatic angiosarcoma and potential treatment options.

Activation of the epidermal growth factor receptor in macrophages regulates cytokine production and experimental colitis.

Maintenance therapy with autologous cytokine-induced killer cells in patients with advanced epithelial ovarian cancer after first-line treatment.

Cancer immunoinformatics: a new assistant tool for malignant disease research.

Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis.

The subsets of dendritic cells and memory T cells correspond to indoleamine 2,3-dioxygenase in stomach tumor microenvironment.

Macrophage immunomodulation by breast cancer-derived exosomes requires Toll-like receptor 2-mediated activation of NF-κB.

Noncanonical NF-κB activation mediates STAT3-stimulated IDO upregulation in myeloid-derived suppressor cells in breast cancer.

TGFβ induces "BRCAness" and sensitivity to PARP inhibition in breast cancer by regulating DNA-repair genes.

Pemetrexed-based chemotherapy in advanced lung adenocarcinoma patients with different EGFR genotypes.

The hOGG1 Ser326Cys polymorphism contributes to digestive system cancer susceptibility: evidence from 48 case-control studies.

Osteopontin is a novel prognostic biomarker in early-stage non-small cell lung cancer after surgical resection.

Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis.

Matrix metalloproteinase 13: a potential intermediate between low expression of microRNA-125b and increasing metastatic potential of non-small cell lung cancer.

Highlights on mechanisms of drugs targeting MDSCs: providing a novel perspective on cancer treatment.

Long non-coding RNA HOTAIR promotes tumor cell invasion and metastasis by recruiting EZH2 and repressing E-cadherin in oral squamous cell carcinoma.

High-mobility group nucleosome-binding protein 1 is a novel clinical biomarker in non-small cell lung cancer.

Role of microRNA-150 in solid tumors.

Regulatory B cell: New member of immunosuppressive cell club.

The role and mechanism of CRL4 E3 ubiquitin ligase in cancer and its potential therapy implications.

IL-8, a novel messenger to cross-link inflammation and tumor EMT via autocrine and paracrine pathways (Review).

Digital Karyotyping with Whole Genomic Sequencing for Complex Congenital Disorder.

Knock-down of CIAPIN1 sensitizes K562 chronic myeloid leukemia cells to Imatinib by regulation of cell cycle and apoptosis-associated members via NF-κB and ERK5 signaling pathway.

Human umbilical cord mesenchymal stem cells delivering sTRAIL home to lung cancer mediated by MCP-1/CCR2 axis and exhibit antitumor effects.

Rapid Response of Advanced Squamous Non-Small Cell Lung Cancer with Thrombocytopenia after First-Line Treatment with Pembrolizumab Plus Autologous Cytokine-Induced Killer Cells.

HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma.

Identification of a three-miRNA signature as a blood-borne diagnostic marker for early diagnosis of lung adenocarcinoma.

Autologous Cytokine-Induced Killer Cells Improves Overall Survival of Metastatic Colorectal Cancer Patients: Results From a Phase II Clinical Trial.

[Analysis of the Role of PET/CT SUVmax in Prognosis and Its Correlation with 
Clinicopathological Characteristics in Resectable Lung Squamous Cell Carcinoma].

A clinically relevant in vivo zebrafish model of human multiple myeloma to study preclinical therapeutic efficacy.

Soluble Toll-like receptor 4 is a potential serum biomarker in non-small cell lung cancer.

Adoptive Cellular Therapy (ACT) for Cancer Treatment.

Profiling the dynamic expression of checkpoint molecules on cytokine-induced killer cells from non-small-cell lung cancer patients.

Positive and negative functions of B lymphocytes in tumors.

An LGG-derived protein promotes IgA production through upregulation of APRIL expression in intestinal epithelial cells.

Relationship of VEGF/VEGFR with immune and cancer cells: staggering or forward?

Plasma miR-324-3p and miR-1285 as diagnostic and prognostic biomarkers for early stage lung squamous cell carcinoma.

BMP signaling and its paradoxical effects in tumorigenesis and dissemination.

Rack1 Mediates the Interaction of P-Glycoprotein with Anxa2 and Regulates Migration and Invasion of Multidrug-Resistant Breast Cancer Cells.

Effects of ulinastatin on early postoperative cognitive function after one-lung ventilation surgery in elderly patients receiving neoadjuvant chemotherapy.

Indoleamine 2,3-dioxygenase regulates T cell activity through Vav1/Rac pathway.

Dysregulation of CUL4A and CUL4B Ubiquitin Ligases in Lung Cancer.

Mesenchymal Cell Reprogramming in Experimental MPLW515L Mouse Model of Myelofibrosis.

[Progress of PD-1/PD-L1 Inhibitors in Non-small Cell Lung Cancer].

Highlights on immune checkpoint inhibitors in non-small cell lung cancer.

Efficacy of ALK5 inhibition in myelofibrosis.

Expression of TLR4 in Non-Small Cell Lung Cancer Is Associated with PD-L1 and Poor Prognosis in Patients Receiving Pulmonectomy.

Prognostic value of pretreatment inflammatory biomarkers in advanced lung adenocarcinoma patients receiving first-line pemetrexed/platinum doublet.

Concurrent somatic mutations in driver genes were significantly correlated with lymph node metastasis and pathological types in solid tumors.

The role of toll-like receptor 4 in tumor microenvironment.

Ginsenoside Rg3 attenuates cisplatin resistance in lung cancer by downregulating PD-L1 and resuming immune.

Cytokine-Induced Killer Cells Modulates Resistance to Cisplatin in the A549/DDP Cell Line.

Herceptin Enhances the Antitumor Effect of Natural Killer Cells on Breast Cancer Cells Expressing Human Epidermal Growth Factor Receptor-2.

[Efficacy and Survival Analysis of Apatinib in Patients with Advanced Nonsquamous Non-small Cell Lung Cancer after Failure of First-line Treatment].

Interleukin-6 -Signaling Pathway Promotes Immunosuppressive Myeloid-Derived Suppressor Cells Suppression of Suppressor of Cytokine Signaling 3 in Breast Cancer.

Phosphoglyceric acid mutase-1 contributes to oncogenic mTOR-mediated tumor growth and confers non-small cell lung cancer patients with poor prognosis.

MicroRNA-544 promotes colorectal cancer progression by targeting forkhead box O1.

Chemotherapy Induces Breast Cancer Stemness in Association with Dysregulated Monocytosis.

New Insights into Tumor-Infiltrating B Lymphocytes in Breast Cancer: Clinical Impacts and Regulatory Mechanisms.

A novel MDSC-induced PD-1PD-L1 B-cell subset in breast tumor microenvironment possesses immuno-suppressive properties.

Cancer-cell-secreted exosomal miR-105 promotes tumour growth through the MYC-dependent metabolic reprogramming of stromal cells.

High Indoleamine 2,3-Dioxygenase Is Correlated With Microvessel Density and Worse Prognosis in Breast Cancer.

New insights into the biological impacts of immune cell-derived exosomes within the tumor environment.

Efficiency of Cytokine-Induced Killer Cells in Combination with Chemotherapy for Triple-Negative Breast Cancer.

Prognostic Significance of BCL-2 and BCL-6 Expression in MYC-positive DLBCL.

A new perspective: Exploring future therapeutic strategies for cancer by understanding the dual role of B lymphocytes in tumor immunity.

PD-1/PD-L1 Axis, Rather Than High-Mobility Group Alarmins or CD8+ Tumor-Infiltrating Lymphocytes, Is Associated With Survival in Head and Neck Squamous Cell Carcinoma Patients Who Received Surgical Resection.

Diprophylline inhibits non-small cell lung cancer A549 cell proliferation and migration, and promotes apoptosis, by downregulating PI3K signaling pathway.

Tumor CD73/A2aR adenosine immunosuppressive axis and tumor-infiltrating lymphocytes in diffuse large B-cell lymphoma: correlations with clinicopathological characteristics and clinical outcome.

Clinical Significance of Serum Type III Interferons in Patients with Gastric Cancer.

Chemoradiotherapy-Induced CD4 and CD8 T-Cell Alterations to Predict Patient Outcomes in Esophageal Squamous Cell Carcinoma.

Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial.

Nociceptin Receptor Is Overexpressed in Non-small Cell Lung Cancer and Predicts Poor Prognosis.

Plasma soluble programmed death ligand 1 levels predict clinical response in peripheral T-cell lymphomas.

Chemotherapy-Induced Extracellular Vesicle miRNAs Promote Breast Cancer Stemness by Targeting .

Memory stem T cells generated by Wnt signaling from blood of human renal clear cell carcinoma patients.

Nicotine promotes the development of non-small cell lung cancer through activating LINC00460 and PI3K/Akt signaling.

Diagnostic value of ProGRP for small cell lung cancer in different stages.

Prognostic Value of the Neo-Immunoscore in Renal Cell Carcinoma.

T-cell receptor gene therapy targeting melanoma-associated antigen-A4 by silencing of endogenous TCR inhibits tumor growth in mice and human.

LINE-1 Retrotransposition Promotes the Development and Progression of Lung Squamous Cell Carcinoma by Disrupting the Tumor-Suppressor Gene FGGY.

New insight on the correlation of metabolic status on F-FDG PET/CT with immune marker expression in patients with non-small cell lung cancer.

Factors related to rapid progression of non-small cell lung cancer in Chinese patients treated using single-agent immune checkpoint inhibitor treatment.

An open label, multicenter, noninterventional study of apatinib in advanced gastric cancer patients (AHEAD-G202).

Safety and effectiveness of apatinib in patients with previously treated metastatic gastric cancer: a sub-analysis from the real-world study of apatinib for gastric cancer treatment (AHEAD-G202).

Prognosis significance of indoleamine 2, 3-dioxygenase, programmed death ligand-1 and tumor-infiltrating immune cells in microenvironment of breast cancer.

Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial.

Primary tumor standardized uptake value (SUVmax) measured on F-FDG PET/CT and mixed NSCLC components predict survival in surgical-resected combined small-cell lung cancer.

Chromosome Abnormalities: New Insights into Their Clinical Significance in Cancer.

Feasibility of sleeve lobectomy after neo-adjuvant chemo-immunotherapy in non-small cell lung cancer.

Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11).

Expression level of PD-L1 is involved in ALDH1A1-mediated poor prognosis in patients with head and neck squamous cell carcinoma.

Expression signature, prognosis value, and immune characteristics of Siglec-15 identified by pan-cancer analysis.

Comprehensive insights into the effects and regulatory mechanisms of immune cells expressing programmed death-1/programmed death ligand 1 in solid tumors.

The Clinical Significance of SIRT2 in Malignancies: A Tumor Suppressor or an Oncogene?

Randomized, multicenter, open-label trial of autologous cytokine-induced killer cell immunotherapy plus chemotherapy for squamous non-small-cell lung cancer: NCT01631357.

Significantly different immunological score in lung adenocarcinoma and squamous cell carcinoma and a proposal for a new immune staging system.

Plasma soluble PD-L1 and STAT3 predict the prognosis in diffuse large B cell lymphoma patients.

Autologous cytokine-induced killer (CIK) cells enhance the clinical response to PD-1 blocking antibodies in patients with advanced non-small cell lung cancer: A preliminary study.

Genetic Mutations of Tim-3 Ligand and Exhausted Tim-3 CD8 T Cells and Survival in Diffuse Large B Cell Lymphoma.

Exhausted T cells and epigenetic status.

Efficacy and safety of apatinib for the treatment of AFP-producing gastric cancer.

Consistency of genotyping data from simultaneously collected plasma circulating tumor DNA and tumor-DNA in lung cancer patients.

Survival benefit and toxicity profile of adjuvant icotinib for patients with mutation-positive non-small cell lung carcinoma: a retrospective study.

Morphine-3-glucuronide upregulates PD-L1 expression TLR4 and promotes the immune escape of non-small cell lung cancer.

Corrigendum to "Genetic Mutations of Tim-3 Ligand and Exhausted Tim-3 CD8 T Cells and Survival in Diffuse Large B Cell Lymphoma".

Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label, phase I dose escalation and dose expansion trial.

Lung cancer-associated mesenchymal stem cells promote tumor metastasis and tumorigenesis by induction of epithelial-mesenchymal transition and stem-like reprogram.

Single-Cell Sequencing Reveals the Transcriptome and TCR Characteristics of pTregs and Expanded iTregs.

Reduced radiotherapy clinical benefit for primary Waldeyer's ring diffuse large B-cell lymphoma in the rituximab era.

Myeloid-derived suppressor cells regulate the immunosuppressive functions of PD-1PD-L1 Bregs through PD-L1/PI3K/AKT/NF-κB axis in breast cancer.

Identification of Key Genes With Differential Correlations in Lung Adenocarcinoma.

Neoadjuvant chemoimmunotherapy in resectable stage IIIA/IIIB non-small cell lung cancer.

An Immune-Clinical Prognostic Index (ICPI) for Patients With Follicular Lymphoma Treated With R-CHOP/CHOP Chemotherapy.

Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study.

TIM-3 and CEACAM1 are Prognostic Factors in Head and Neck Squamous Cell Carcinoma.

Ferritin as a diagnostic, differential diagnostic, and prognostic marker for immune-related adverse events.

Somatic copy number alterations are predictive of progression-free survival in patients with lung adenocarcinoma undergoing radiotherapy.

The prognostic landscape of genes and infiltrating immune cells in cytokine induced killer cell treated-lung squamous cell carcinoma and adenocarcinoma.

Bortezomib enhances the anti-cancer effect of the novel Bruton's tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK.

Programmed Cell Death Protein 1/Programmed Cell Death Ligand-1 Axis activates Intracellular ERK Signaling in Tumor Cells to Mediate Poor Prognosis in T-cell Lymphoma.

Insights into tertiary lymphoid structures in the solid tumor microenvironment: anti-tumor mechanism, functional regulation, and immunotherapeutic strategies.

EZH2 identifies the precursors of human natural killer cells with trained immunity.

Tracking the evolution of untreated high-intermediate/high-risk diffuse large B-cell lymphoma by circulating tumour DNA.

Comprehensive analysis of TP53 mutation characteristics and identification of patients with inferior prognosis and enhanced immune escape in diffuse large B-cell lymphoma.

The Distinct Impact of TAM Infiltration on the Prognosis of Patients With Cardia and Non-Cardia Gastric Cancer and Its Association With Infection.

The Sequence of Chemotherapy and Toripalimab Might Influence the Efficacy of Neoadjuvant Chemoimmunotherapy in Locally Advanced Esophageal Squamous Cell Cancer-A Phase II Study.

Somatic copy number alteration predicts clinical benefit of lung adenocarcinoma patients treated with cytokine-induced killer plus chemotherapy.

High Complete Response Rate in Patients With Metastatic Renal Cell Carcinoma Receiving Autologous Cytokine-Induced Killer Cell Therapy Plus Anti-Programmed Death-1 Agent: A Single-Center Study.

A phase I study of FCN-411, a pan-HER inhibitor, in EGFR-mutated advanced NSCLC after progression on EGFR tyrosine kinase inhibitors.

Downregulation of PD-L1 and HLA-I in non-small cell lung cancer with ALK fusion.

Safety and effectiveness of pembrolizumab combined with paclitaxel and cisplatin as neoadjuvant therapy followed by surgery for locally advanced resectable (stage III) esophageal squamous cell carcinoma: a study protocol for a prospective, single-arm, single-center, open-label, phase-II trial (Keystone-001).

Genetic characteristics involving the PD-1/PD-L1/L2 and CD73/A2aR axes and the immunosuppressive microenvironment in DLBCL.

A novel clinical immune-related prognostic model predicts the overall survival of mantle cell lymphoma.

PIM1 genetic alterations associated with distinct molecular profiles, phenotypes and drug responses in diffuse large B-cell lymphoma.

Prediction of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint inhibitors based on clinical and hematological markers: Real-world evidence.

Pembrolizumab Combined With Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Locally Advanced Oesophageal Squamous Cell Carcinoma: Protocol for a Multicentre, Prospective, Randomized-Controlled, Phase III Clinical Study (Keystone-002).

Relationship and prognostic significance of IL-33, PD-1/PD-L1, and tertiary lymphoid structures in cervical cancer.

CD4 T cells are required to improve the efficacy of CIK therapy in non-small cell lung cancer.

Screening of Adverse Prognostic Factors and Construction of Prognostic Index in Previously Untreated Concurrent Follicular Lymphoma and Diffuse Large B-Cell Lymphoma.

Tumor-Resident T Cells, Associated With Tertiary Lymphoid Structure Maturity, Improve Survival in Patients With Stage III Lung Adenocarcinoma.

PGAM1 regulation of ASS1 contributes to the progression of breast cancer through the cAMP/AMPK/CEBPB pathway.

Dysregulated Th1 cells in lung squamous cell carcinoma.

m6A-Regulator Expression Signatures Identify a Subset of Follicular Lymphoma Harboring an Exhausted Tumor Microenvironment.

Trained Immunity of IL-12-, IL-15-, and IL-18-Induced CD+CD+ NKT-Like Cells.

Single-cell profiling of immune cells after neoadjuvant pembrolizumab and chemotherapy in IIIA non-small cell lung cancer (NSCLC).

A 9-LncRNA Signature for Predicting Prognosis and Immune Response in Diffuse Large B-Cell Lymphoma.

Cancer immunology and immunotherapy.

A Phase IB Trial of Autologous Cytokine-Induced Killer Cells in Combination with Sintilimab, Monoclonal Antibody Against Programmed Cell Death-1, plus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer.

A novel immune-related epigenetic signature based on the transcriptome for predicting the prognosis and therapeutic response of patients with diffuse large B-cell lymphoma.

The prognostic value of a 4-factor neoimmunologic score system in non-small cell lung cancer.

Safety and effectiveness of apatinib in elderly patients with metastatic gastric cancer: a sub-analysis from the large-scale, prospective observational study of apatinib for gastric cancer treatment in a real-world clinical setting (AHEAD-G202).

Clinical features and outcomes of patients with follicular lymphoma: A real-world study of 926 patients in China.

Rational pemetrexed combined with CIK therapy plus anti-PD-1 mAbs administration sequence will effectively promote the efficacy of CIK therapy in non-small cell lung cancer.

Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 Trial.

Therapeutic effect of haploidentical peripheral blood stem cell treatment on relapsed/refractory ovarian cancer.

SOCS3 deficiency-dependent autophagy repression promotes the survival of early-stage myeloid-derived suppressor cells in breast cancer by activating the Wnt/mTOR pathway.

[Study on the Biological Function of Abemecilib in Inhibiting the Proliferation, Invasion and
Migration of Small Cell Lung Cancer with High c-Myc Expression].

Novel strategies for cancer immunotherapy: counter-immunoediting therapy.

DC101, an anti-VEGFR2 agent, promotes high-endothelial venule formation and immune infiltration versus SAR131675 and fruquintinib.

OX40 shapes an inflamed tumor immune microenvironment and predicts response to immunochemotherapy in diffuse large B-cell lymphoma.

PD-1 blockade potentiates neoadjuvant chemotherapy in NSCLC via increasing CD127 and KLRG1 CD8 T cells.

Integrative genomic and transcriptomic analysis reveals genetic alterations associated with the early progression of follicular lymphoma.

In vitro CRISPR screening uncovers CRTC3 as a regulator of IFN-γ-induced ferroptosis of hepatocellular carcinoma.

Effect of Chemotherapeutics on In Vitro Immune Checkpoint Expression in Non-Small Cell Lung Cancer.

Blocking Tim-3 enhances the anti-tumor immunity of STING agonist ADU-S100 by unleashing CD4 T cells through regulating type 2 conventional dendritic cells.

Single-cell transcriptomics reveals tumor-infiltrating B cell function after neoadjuvant pembrolizumab and chemotherapy in non-small cell lung cancer.

Correction: In vitro CRISPR screening uncovers CRTC3 as a regulator of IFN-γ-induced ferroptosis of hepatocellular carcinoma.

Examining the spatial distribution of tumor-infiltrating immune cells in patients with stage I to IIIA LUAD.

Cytokine-induced killer (CIK) cells, successes and challenges: report on the first international conference dedicated to the clinical translation of this unique adoptive cell immunotherapy.

The spatial landscape of T cells in the microenvironment of stage III lung adenocarcinoma.

STING licensing of type I dendritic cells potentiates antitumor immunity.

Anlotinib and anti-PD-1 mAbs perfected CIK cell therapy for lung adenocarcinoma in preclinical trials.

Effects of immunogenic cell death-inducing chemotherapeutics on the immune cell activation and tertiary lymphoid structure formation in melanoma.

Immune checkpoint ligands expressed on mature high endothelial venules predict poor prognosis of NSCLC: have a relationship with CD8 T lymphocytes infiltration.

Epidemiological features and prognosis for primary gastrointestinal follicular lymphoma.

PGAM1 suppression remodels the tumor microenvironment in triple-negative breast cancer and synergizes with anti-PD-1 immunotherapy.

Intratumor tertiary lymphatic structure evaluation predicts the prognosis and immunotherapy response of patients with colorectal cancer.

XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer: a multicenter, open-label, randomized, controlled, phase 3 trial.

The Role of Natural Killer Cells in the Tumor Immune Microenvironment of EBV-Associated Nasopharyngeal Carcinoma.

Peripheral NK cells identified as the predictor of response in extensive-stage small cell lung cancer patients treated with first-line immunotherapy plus chemotherapy.

Phosphoglycerate mutase 1 promotes breast cancer progression through inducing immunosuppressive M2 macrophages.

The antitumor effect of extracellular vesicles derived from cytokine-activated CD8+ T cells.

Corrigendum: Intratumor tertiary lymphatic structure evaluation predicts the prognosis and immunotherapy response of patients with colorectal cancer.

Establishment of an animal model of immune-related adverse events induced by immune checkpoint inhibitors.

Novel FABP4C1q macrophages enhance antitumor immunity and associated with response to neoadjuvant pembrolizumab and chemotherapy in NSCLC via AMPK/JAK/STAT axis.

Toripalimab in combination with HBM4003, an anti-CTLA-4 heavy chain-only antibody, in advanced melanoma and other solid tumors: an open-label phase I trial.

A prospective study of neoadjuvant pembrolizumab plus chemotherapy for resectable esophageal squamous cell carcinoma: The Keystone-001 trial.

Advances in adoptive cellular immunotherapy and therapeutic breakthroughs in multiple myeloma.

First-line treatment with gefitinib in combination with bevacizumab and chemotherapy in advanced non-squamous NSCLC with EGFR-mutation.

Association of concomitant H1 antihistamine and immune checkpoint inhibitor therapy on survival outcome and safety in patients with advanced primary lung cancer: a cohort study.

Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study.

Elucidating the synergistic roles of CD4+ T and dendritic cells in antitumor immunity.